Indeed, the results obtained represent the rationale for an independent clinical trial (AZ and EG, personal communication), which we will conduct in post-menopausal patients suffering from ER+ breast cancer aimed at evaluating the efficacy of ATRA addition to aromatase inhibitors. Here, CYP19A1 is linked to breast carcinoma.